What are you searching for?

Sign in
Breaking News, Promotions & Moves

Oncobiologics Appoints CEO

Lawrence A. Kenyon was previously CFO and corporate secretary at the company, and brings over 20 years experience

By: Betsy Louda

, Contract Pharma

Oncobiologics announced that Lawrence A. Kenyon, its chief financial officer and corporate secretary, has been appointed to the role of president and chief executive officer, and has joined the Company’s Board of Directors as a class II director. Mr. Kenyon will remain as chief financial officer until a replacement is appointed.

“On behalf of the Oncobiologics board of directors, we are very pleased to name Larry as President and CEO as well as his appointment to the board of directors,” said Randy Thurman, Oncobiologics’ executive chairman.  “Larry’s experience and demonstrated leadership are an ideal fit for Oncobiologics as we move our lead program into the clinic and address the other strategies instrumental to the company’s success.  The company’s senior leadership team is an ideal complement to Larry’s background and represents one of the best in the biopharma industry.”

Mr. Kenyon was appointed interim chief executive officer at Oncobiologics in June 2018 after he joined Oncobiologics as chief financial officer and corporate secretary in September 2015. He is an experienced industry executive with nearly 20 years of leadership in the life sciences industry.

“I am honored by the trust and confidence shown by the board,” said Mr. Kenyon. “Our lead asset, ONS-5010, presents an exciting opportunity to meet the need for an important and affordable therapeutic option for patients. I look forward to working with the board and our very talented senior leadership team to execute on our strategy to maximize value for all Oncobiologics stockholders.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters